Phase II
There was a fair amount of clinical trial news last week. Here’s a look.
With oncology drugs clocking a disheartening 3.4% success rate, some good news in the field is always appreciated.
The study involved observations in neurologic function, cognition and biomarkers in three repeated administrations of Nurown®, which were given two months apart.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look.
It will evaluate about 440 patients and the treatments’ effect on liver fibrosis improvement and NASH resolution.
Infectious disease-focused Vaccitech, which partnered with AstraZeneca and Oxford University on the development and manufacturing of that company’s COVID-19 vaccine, raised $168 million in a Series B financing round.
Topline data from Merck KGaA’s Phase II INTR@PID BTC 047 study show bintrafusp alfa has single-agent efficacy and safety in the second-line treatment of locally advanced or metastatic biliary tract cancer in patients who have either failed or are intolerant to first-line platinum-based chemotherapy.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 16, 2021.
Nearly five years to the day after striking the deal, AVEO Oncology and CANbridge Life Sciences announce the termination of their collaboration and licensing agreement for AVEO’s AV-203.
PRESS RELEASES